Tuesday, Nov 29, 2022

Ajanta Pharma gets USFDA observation for Paithan facility

"We are in process of responding to the same within the stipulated time prescribed by US FDA," Ajanta Pharma said.

Drug firm Ajanta Pharma today said the US health regulator has issued one observation for its Paithan facility in Aurangabad after the inspection.

“This is to inform that our Paithan facility was recently inspected by the US FDA and we are issued one procedural related 483,” Ajanta Pharma said in a BSE filing.

It further said: “We are in process of responding to the same within the stipulated time prescribed by US FDA.”

Shares of Ajanta Pharma were trading 1.84 per cent higher at Rs 1,791.50 on the BSE.

Subscriber Only Stories
JK Cement’s SPSU Udaipur Launches ‘Golden Batch 2022’ In Collaboration Wi...Premium
Appendicitis in Children- A new lifestyle disorderPremium
Using evidence will create strong foundations for the future of education...Premium
Re-Defining The Tradition In Folk Art: An Art Educator’s PerspectivePremium

First published on: 09-02-2017 at 11:24:27 am
Next Story

Panneerselvam issues orders to convert Jayalalithaa’s Poes Garden residence into memorial

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
close